• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国肝移植的结局:韩国移植登记处的发生率和危险因素。

Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry.

机构信息

Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea.

出版信息

Clin Mol Hepatol. 2021 Jul;27(3):451-462. doi: 10.3350/cmh.2020.0292. Epub 2021 Feb 2.

DOI:10.3350/cmh.2020.0292
PMID:33525077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8273644/
Abstract

BACKGROUND/AIMS: To analyze the incidence and risk factors of outcomes after liver transplantation (LT) in the Korean population.

METHODS

This study analyzed data from the liver cohort of Korean Organ Transplantation Registry (KOTRY) who had LT between May 2014 and December 2017. Study measures included the incidence of post-LT outcomes in recipients of living donor LT (LDLT) and deceased donor LT (DDLT). Cox multivariate proportional hazards model was used to determine the potential risk factors predicting the outcomes.

RESULTS

A total of 2,563 adult recipients with LT (LDLT, n=1,956; DDLT, n=607) were included, with mean±standard deviation age of 53.9±8.9 years, and 72.2% were male. The post-LT outcomes observed in each LDLT and DDLT recipients were death (4.0% and 14.7%), graft loss (5.0% and 16.1%), rejection (7.0% and 12.0%), renal failure (2.7% and 13.8%), new onset of diabetes (12.5% and 15.4%), and hepatocellular carcinoma (HCC) recurrence (both 6.7%). In both LDLT and DDLT recipients, the most common post-LT complications were renal dysfunction (33.6% and 51.4%), infection (26.7% and 48.4%), and surgical complication (22.5% and 23.9%). Incidence of these outcomes were generally higher among recipients of DDLT than LDLT. Multivariate analysis indicated recipient age and DDLT as significant risk factors associated with death and graft loss. DDLT and ABO incompatible transplant were prognostic factors for rejection, and HCC beyond Milan criteria at pre-transplant was a strong predictor of HCC recurrence.

CONCLUSION

This study is a good indicator of the post-LT prognosis in the Korean population and suggests a significant burden of post-LT complications.

摘要

背景/目的:分析韩国人群肝移植(LT)后结局的发生率和相关风险因素。

方法

本研究分析了 2014 年 5 月至 2017 年 12 月期间韩国器官移植登记处(KOTRY)肝移植队列中接受活体供体肝移植(LDLT)和尸体供体肝移植(DDLT)的受者的 LT 后结局发生率。研究指标包括 LDLT 和 DDLT 受者的 LT 后结局发生率。采用 Cox 多变量比例风险模型确定预测结局的潜在风险因素。

结果

共纳入 2563 例成人 LT 受者(LDLT,n=1956;DDLT,n=607),平均年龄(53.9±8.9)岁,72.2%为男性。LDLT 和 DDLT 受者的 LT 后结局分别为死亡(4.0%和 14.7%)、移植物失功(5.0%和 16.1%)、排斥反应(7.0%和 12.0%)、肾衰竭(2.7%和 13.8%)、新发糖尿病(12.5%和 15.4%)和肝细胞癌(HCC)复发(均为 6.7%)。在 LDLT 和 DDLT 受者中,最常见的 LT 后并发症为肾功能障碍(33.6%和 51.4%)、感染(26.7%和 48.4%)和手术并发症(22.5%和 23.9%)。DDLT 受者的这些结局发生率通常高于 LDLT 受者。多变量分析表明,受者年龄和 DDLT 是与死亡和移植物失功相关的显著风险因素。DDLT 和 ABO 不相容移植是排斥反应的预后因素,而移植前米兰标准以外的 HCC 是 HCC 复发的强预测因素。

结论

本研究为韩国人群 LT 后预后提供了良好的指标,并提示 LT 后并发症负担较重。

相似文献

1
Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry.韩国肝移植的结局:韩国移植登记处的发生率和危险因素。
Clin Mol Hepatol. 2021 Jul;27(3):451-462. doi: 10.3350/cmh.2020.0292. Epub 2021 Feb 2.
2
Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.活体供肝移植与死亡供肝移植相比,肝癌复发率更高。
Transplantation. 2014 Jan 15;97(1):71-7. doi: 10.1097/TP.0b013e3182a68953.
3
Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.在 MELD 时代肝移植后肝细胞癌复发的发生率和危险因素。
Dig Dis Sci. 2012 Mar;57(3):806-12. doi: 10.1007/s10620-011-1910-9. Epub 2011 Sep 28.
4
Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.成人对成人活体肝移植队列研究中的复发性原发性硬化性胆管炎:活体供肝与尸体供肝受者的危险因素比较
Liver Transpl. 2016 Sep;22(9):1214-22. doi: 10.1002/lt.24496. Epub 2016 Aug 2.
5
Clinical outcomes after ABO-incompatible liver transplantation: A systematic review and meta-analysis.ABO 不相容肝移植后的临床结局:系统评价和荟萃分析。
Transpl Immunol. 2021 Dec;69:101476. doi: 10.1016/j.trim.2021.101476. Epub 2021 Oct 1.
6
Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.与尸体供肝移植相比,活体供肝移植不会增加肝细胞癌的肿瘤复发率。
World J Gastroenterol. 2014 Aug 21;20(31):10953-9. doi: 10.3748/wjg.v20.i31.10953.
7
Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond milan criteria.小体积供肝移植增加了米兰标准以外肝癌肝移植的复发率。
Liver Transpl. 2018 Jan;24(1):35-43. doi: 10.1002/lt.24868.
8
Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma.活体与尸体供肝肝移植治疗肝细胞癌的对比研究
J Am Coll Surg. 2015 Mar;220(3):297-304.e3. doi: 10.1016/j.jamcollsurg.2014.12.009. Epub 2014 Dec 13.
9
A comparison of rates and severity of chronic kidney disease in deceased-donor and living-donor liver transplant recipients: times matter.比较死亡供体和活体供体肝移植受者的慢性肾脏病发生率和严重程度:时间很重要。
Turk J Med Sci. 2021 Apr 30;51(2):610-622. doi: 10.3906/sag-2007-82.
10
Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses.活体供肝与尸体供肝肝移植治疗肝细胞癌的长期生存结局:意向治疗和倾向评分匹配分析。
Ann Surg Oncol. 2019 May;26(5):1454-1462. doi: 10.1245/s10434-019-07206-0. Epub 2019 Feb 8.

引用本文的文献

1
The evaluation of inflammatory and immune composite markers for complications after deceased donor liver transplantation - a retrospective cohort study.deceased供体肝移植术后并发症的炎症和免疫复合标志物评估——一项回顾性队列研究
Ann Med. 2025 Dec;57(1):2536757. doi: 10.1080/07853890.2025.2536757. Epub 2025 Jul 24.
2
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".他克莫司谷浓度的患者内变异性可能并非病因,而是合并症的一个间接参数:关于“降低慢性肾脏病风险的他克莫司最佳水平以及患者内变异性对肝移植后慢性肾脏病和终末期肾病发展的影响”的社论
Clin Mol Hepatol. 2025 Apr;31(2):589-591. doi: 10.3350/cmh.2025.0076. Epub 2025 Jan 24.
3

本文引用的文献

1
New-onset diabetes after adult liver transplantation in the Korean Organ Transplantation Registry (KOTRY) study.韩国器官移植登记处(KOTRY)研究中的成人肝移植后新发糖尿病。
Hepatobiliary Surg Nutr. 2020 Aug;9(4):425-439. doi: 10.21037/hbsn.2019.10.29.
2
Adult Living Donor Versus Deceased Donor Liver Transplant (LDLT Versus DDLT) at a Single Center: Time to Change Our Paradigm for Liver Transplant.单中心成人活体供肝与尸体供肝肝移植(LDLT 与 DDLT):是时候改变我们的肝移植模式了。
Ann Surg. 2019 Sep;270(3):444-451. doi: 10.1097/SLA.0000000000003463.
3
Development of a Korean Liver Allocation System using Model for End Stage Liver Disease Scores: A Nationwide, Multicenter study.
Effect of Medical Accessibility on Long-Term Survival in Liver Transplantation.医疗可及性对肝移植长期生存的影响
Ann Transplant. 2024 Dec 17;29:e944839. doi: 10.12659/AOT.944839.
4
Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation.联合使用免疫抑制剂和乙型肝炎病毒抗病毒药物对活体供肝移植受者接种新冠病毒疫苗的影响。
PeerJ. 2024 Dec 6;12:e18651. doi: 10.7717/peerj.18651. eCollection 2024.
5
Mortality and associated factors among patients who underwent liver transplantation in South Korea from 2017 to 2021: a retrospective observational study.2017年至2021年韩国肝移植患者的死亡率及相关因素:一项回顾性观察研究
Ann Surg Treat Res. 2024 Nov;107(5):245-251. doi: 10.4174/astr.2024.107.5.245. Epub 2024 Oct 29.
6
Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis.壳三糖酶蛋白 1 是合并肌内脂肪变性的肝细胞癌患者的预后生物标志物。
BMC Cancer. 2024 Aug 23;24(1):1042. doi: 10.1186/s12885-024-12808-3.
7
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation.ABO血型不相容肝移植中早期血清他克莫司高水平与肝细胞癌复发之间的关联
World J Gastrointest Surg. 2023 Dec 27;15(12):2727-2738. doi: 10.4240/wjgs.v15.i12.2727.
8
The Effect of Model for End-Stage Liver Disease 3.0 on Disparities between Patients with and without Hepatocellular Carcinoma in Korea.模型预测终末期肝病 3.0 对韩国肝癌患者和非肝癌患者之间差异的影响。
Yonsei Med J. 2023 Nov;64(11):647-657. doi: 10.3349/ymj.2023.0163.
9
Cancer Incidence in Living Liver Donors After Donor Hepatectomy.活体肝移植供者肝切除术后的癌症发病率。
J Korean Med Sci. 2023 Sep 4;38(35):e277. doi: 10.3346/jkms.2023.38.e277.
10
Evidence-based hyponatremia management in liver disease.基于证据的肝脏疾病低钠血症管理。
Clin Mol Hepatol. 2023 Oct;29(4):924-944. doi: 10.3350/cmh.2023.0090. Epub 2023 Jun 5.
应用终末期肝脏疾病评分模型开发韩国肝脏分配系统:一项全国性、多中心研究。
Sci Rep. 2019 May 16;9(1):7495. doi: 10.1038/s41598-019-43965-2.
4
Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective.活体肝移植治疗肝细胞癌:亚洲视角。
Dig Dis Sci. 2019 Apr;64(4):993-1000. doi: 10.1007/s10620-019-05551-4.
5
Renal Dysfunction after Living-Donor Liver Transplantation: Experience with 500 Cases.活体肝移植术后的肾功能障碍:500例经验
J Transplant. 2018 Dec 23;2018:5910372. doi: 10.1155/2018/5910372. eCollection 2018.
6
Age and liver transplantation.年龄与肝移植。
J Hepatol. 2019 Apr;70(4):745-758. doi: 10.1016/j.jhep.2018.12.009. Epub 2018 Dec 18.
7
Living or deceased organ donors in liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis.肝细胞癌肝移植中活体或已故器官供体:系统评价与荟萃分析
HPB (Oxford). 2019 Feb;21(2):133-147. doi: 10.1016/j.hpb.2018.11.004. Epub 2018 Nov 30.
8
The changing epidemiology of liver diseases in the Asia-Pacific region.亚太地区肝脏疾病的不断变化的流行病学。
Nat Rev Gastroenterol Hepatol. 2019 Jan;16(1):57-73. doi: 10.1038/s41575-018-0055-0.
9
Recipient Age and Mortality After Liver Transplantation: A Population-based Cohort Study.受体年龄与肝移植术后死亡率:基于人群的队列研究。
Transplantation. 2018 Dec;102(12):2025-2032. doi: 10.1097/TP.0000000000002246.
10
Liver Transplantation Today: Where We Are Now and Where We Are Going.肝脏移植的今天:我们现在在哪里,以及我们要去哪里。
Liver Transpl. 2018 Oct;24(10):1470-1475. doi: 10.1002/lt.25320.